Mal Interacts with Tumor Necrosis Factor Receptor-associated Factor (TRAF)-6 to mediate NF-κB Activation by Toll-like Receptor (TLR)-2 and TLR4

Ashley Mansell, Elizabeth Brint, Jodee A. Gould, Luke O'neill, Paul J. Hertzog

Journal of Biological Chemistry · 2004 · 116 citations · 18 references

DOIFull text

Open access

Concepts

Abstract

The Toll-interleukin-1 receptor domain-containing adapter Mal (MyD88 adapter-like protein) is involved in Toll-like receptor (TLR)-2 and TLR4 signal transduction. However, no studies have yet identified a function for Mal distinct from the related adapter MyD88. In this study, we have identified a putative TRAF6 interaction site in Mal but not in MyD88 and we demonstrate that Mal can be co-immunoprecipitated with TRAF6. Overexpression of MalE190A, which contains a mutation within the TRAF6-binding motif, failed to induce the expression of an NF-κB-dependent reporter gene, p65-mediated transactivation of gene expression, or activation of Jun N-terminal kinase or p42/p44 MAP kinase, which are induced with wild type Mal. MalE190A inhibited TLR2- and TLR4-mediated activation of NF-κB. These results identify a specific role for Mal in TLR-mediated signaling in regulating NF-κB-dependent gene transcription via its interaction with TRAF6. The Toll-interleukin-1 receptor domain-containing adapter Mal (MyD88 adapter-like protein) is involved in Toll-like receptor (TLR)-2 and TLR4 signal transduction. However, no studies have yet identified a function for Mal distinct from the related adapter MyD88. In this study, we have identified a putative TRAF6 interaction site in Mal but not in MyD88 and we demonstrate that Mal can be co-immunoprecipitated with TRAF6. Overexpression of MalE190A, which contains a mutation within the TRAF6-binding motif, failed to induce the expression of an NF-κB-dependent reporter gene, p65-mediated transactivation of gene expression, or activation of Jun N-terminal kinase or p42/p44 MAP kinase, which are induced with wild type Mal. MalE190A inhibited TLR2- and TLR4-mediated activation of NF-κB. These results identify a specific role for Mal in TLR-mediated signaling in regulating NF-κB-dependent gene transcription via its interaction with TRAF6. MyD88 adapter-like protein (Mal) 1The abbreviations used are: Mal, MyD88 adapter-like protein; TIR, Toll/IL-1 receptor; TLR, Toll-like receptor; TRIF, TIR-containing adapter inducing interferon β; TRAM, TRIF-related adapter molecule; LPS, lipopolysaccharide; IL, interleukin; HEK, human embryonic kidney; pI:C, poly(I)·poly(C); HA, hemagglutinin; JNK, c-Jun N-terminal kinase; MAP, mitogen-activated protein. IRAK, IL-1 receptor-associated kinase. (also known as Toll/IL-1 receptor (TIR) domain-containing adapter protein (TIRAP)) (1Fitzgerald K.A. Palsson-McDermott E.M. Bowie A.G. Jefferies C.A. Mansell A.S. Brady G. Brint E. Dunne A. Gray P. Harte M.T. McMurray D. Smith D.E. Sims J.E. Bird T.A. O'Neill L.A. Nature. 2001; 413: 78-83Crossref PubMed Scopus (1005) Google Scholar, 2Horng T. Barton G.M. Medzhitov R. Nat. Immunol. 2001; 2: 835-841Crossref PubMed Scopus (832) Google Scholar) is a member of the family of the TIR domain-containing adapter proteins involved in Toll-like receptor (TLR) signaling (3O'Neill L.A. Fitzgerald K.A. Bowie A.G. Trends Immunol. 2003; 24: 286-290Abstract Full Text Full Text PDF PubMed Scopus (418) Google Scholar, 4Yamamoto M. Takeda K. Akira S. Mol. Immunol. 2004; 40: 861-868Crossref PubMed Scopus (304) Google Scholar). MyD88 was the first adapter in the family to be described, and it plays a role in signal transduction by all TLRs, with the exception of TLR3 (5Janssens S. Beyaert R. Trends Biochem. Sci. 2002; 27: 474-482Abstract Full Text Full Text PDF PubMed Scopus (333) Google Scholar). Mal was found as a homologue of MyD88 (1Fitzgerald K.A. Palsson-McDermott E.M. Bowie A.G. Jefferies C.A. Mansell A.S. Brady G. Brint E. Dunne A. Gray P. Harte M.T. McMurray D. Smith D.E. Sims J.E. Bird T.A. O'Neill L.A. Nature. 2001; 413: 78-83Crossref PubMed Scopus (1005) Google Scholar, 2Horng T. Barton G.M. Medzhitov R. Nat. Immunol. 2001; 2: 835-841Crossref PubMed Scopus (832) Google Scholar). In terms of function, it resembles MyD88 in that it is involved in the early activation of NF-κB and MAP kinases, but its use is restricted to signaling by TLR2 and TLR4 (6Horng T. Barton G.M. Flavell R.A. Medzhitov R. Nature. 2002; 420: 329-333Crossref PubMed Scopus (689) Google Scholar, 7Yamamoto M. Sato S. Hemmi H. Sanjo H. Uematsu S. Kaisho T. Hoshino K. Takeuchi O. Kobayashi M. Fujita T. Takeda K. Akira S. Nature. 2002; 420: 324-329Crossref PubMed Scopus (821) Google Scholar). Two further adapters have been found to play a role in TLR signaling. TRIF (TIR-containing adapter inducing interferon β or TICAM-1) (8Oshiumi H. Matsumoto M. Funami K. Akazawa T. Seya T. Nat. Immunol. 2003; 4: 161-167Crossref PubMed Scopus (1014) Google Scholar, 9Yamamoto M. Sato S. Mori K. Hoshino K. Takeuchi O. Takeda K. Akira S. J. Immunol. 2002; 169: 6668-6672Crossref PubMed Scopus (1025) Google Scholar, 10Hoebe K. Du X. Georgel P. Janssen E. Tabeta K. Kim S.O. Goode J. Lin P. Mann N. Mudd S. Crozat K. Sovath S. Han J. Beutler B. Nature. 2003; 424: 743-748Crossref PubMed Scopus (1037) Google Scholar) is necessary for TLR3- and TLR4-mediated activation of NF-κB and another transcription factor IRF3, while TRAM (TRIF-related adapter molecule, also termed TICAM-2) (11Fitzgerald K.A. Rowe D.C. Barnes B.J. Caffrey D.R. Visintin A. Latz E. Monks B. Pitha P.M. Golenbock D.T. J. Exp. Med. 2003; 198: 1043-1055Crossref PubMed Scopus (939) Google Scholar, 12Yamamoto M. Sato S. Hemmi H. Uematsu S. Hoshino K. Kaisho T. Takeuchi O. Takeda K. Akira S. Nat. Immunol. 2003; 4: 1144-1150Crossref PubMed Scopus (832) Google Scholar, 13Oshiumi H. Sasai M. Shida K. Fujita T. Matsumoto M. Seya T. J. Biol. Chem. 2003; 278: 49751-49762Abstract Full Text Full Text PDF PubMed Scopus (331) Google Scholar) is essential for TLR4 signals, including IRF3. LPS-stimulated macrophages from MyD88- and Mal-deficient mice both displayed similar absence of cytokine production and delayed NF-κB activation but were normal for IRF3 activation and interferon β production. A double knock-out suggested that neither protein could compensate for the other. While a role for TRIF and TRAM in the IRF3 pathway distinguishes them from MyD88 and Mal, there is still no functional distinction between MyD88 and Mal in terms of function. Recently, two groups reported the identification and functional role TRIF association with TRAF6 via a TRAF6-binding motif (14Jiang Z. Mak T.W. Sen G. Li X. Proc. Natl. Acad. Sci. U. S. A. 2004; 101: 3533-3538Crossref PubMed Scopus (309) Google Scholar, 15Sato S. Sugiyama M. Yamamoto M. Watanabe Y. Kawai T. Takeda K. Akira S. J. Immunol. 2003; 171: 4304-4310Crossref PubMed Scopus (590) Google Scholar). TRIF was found to mediate TLR3-induced activation of NF-κB via an association with TRAF6, independent of MyD88 and IRAK (15Sato S. Sugiyama M. Yamamoto M. Watanabe Y. Kawai T. Takeda K. Akira S. J. Immunol. 2003; 171: 4304-4310Crossref PubMed Scopus (590) Google Scholar). The TRAF6 interaction motif was based upon work by Pullen et al. (16Pullen S.S. Labadia M.E. Ingraham R.H. McWhirter S.M. Everdeen D.S. Alber T. Crute J.J. Kehry M.R. Biochemistry. 1999; 38: 10168-10177Crossref PubMed Scopus (131) Google Scholar, 17Pullen S.S. Miller H.G. Everdeen D.S. Dang T.T. Crute J.J. Kehry M.R. Biochemistry. 1998; 37: 11836-11845Crossref PubMed Scopus (206) Google Scholar) who first identified a cytoplasmic region of CD40 required to facilitate its binding of the TRAF-C domain of TRAF6. This interaction region was further defined by the elucidation of the crystal structure of the TRAF-C domain of TRAF6 in complex with peptides corresponding to CD40 or TRANCE-R (18Ye H. Arron J.R. Lamothe B. Cirilli M. Kobayashi T. Shevde N.K. Segal D. Dzivenu O.K. Vologodskaia M. Yim M. Du K. Singh S. Pike J.W. Darnay B.G. Choi Y. Wu H. Nature. 2002; 418: 443-447Crossref PubMed Scopus (541) Google Scholar). Structural analysis identified a nominal TRAF6-binding motif consisting of Pro-X-Glu-X-X-aromatic/acidic amino acids. Furthermore, three TRAF6-binding motifs were identified in IRAK, two in IRAK-2, one in IRAK-M, and one in RIP2 (see Table I). Sequential mutation of a critical glutamic acid in one, two, or all three TRAF6-binding motifs in IRAK proportionally attenuated IL-1-induced NF-κB activation.Table IPutative TRAF6-binding motifs in human TIR domain-containing adapters Open table in a new tab In this study we have found that similar to TRIF, Mal has a putative TRAF6-binding motif. The motif is required for Mal to drive signals for NF-κB activation and the interaction between Mal and TRAF6 for downstream signaling events. This provides a distinguishing feature between Mal and MyD88 in TLR2- and TLR4-mediated responses. Cell Lines and Reagents—Human embryonic kidney (HEK) 293, HEK293T, and HEK293 stably transfected cells expressing TLR4 and MD2, were incubated in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 2 mm glutamine and maintained in a 37 °C humidified atmosphere. LPS K235 (Sigma) was repurified as described previously (19Hirschfeld M. Ma Y. Weis J.H. Vogel S.N. Weis J.J. J. Immunol. 2000; 165: 618-622Crossref PubMed Scopus (973) Google Scholar), Pam3Cys was obtained from EMC microcollections (Turbingen, Germany), poly(I)·poly(C) (pI:C) was obtained from Amersham Biosciences (Uppsala, Sweden), and anti-FLAG M2-horseradish peroxidase-conjugated antibody and anti-FLAG M2-agarose beads were from Sigma. Plasmids—Full-length pDC304 Mal-HA, pDC304 Mal-HA N-terminal(1–74), and pDC304 Mal-HA TIR domain(74–235) have been described previously (1Fitzgerald K.A. Palsson-McDermott E.M. Bowie A.G. Jefferies C.A. Mansell A.S. Brady G. Brint E. Dunne A. Gray P. Harte M.T. McMurray D. Smith D.E. Sims J.E. Bird T.A. O'Neill L.A. Nature. 2001; 413: 78-83Crossref PubMed Scopus (1005) Google Scholar). MalE190A was generated using the QuikChange site-directed mutagenesis kit with pfu-Turbo (Stratagene, La Jolla, CA) using the pDC304 Mal-HA template. Gal4-p65(1–551) plasmid encoding the full-length p65 subunit of NF-κB fused to Gal4 DNA-binding domain was a kind gift from Lienhard Schmitz (German Cancer Research Centre, Heidelburg, Germany) (20Jefferies C. Bowie A. Brady G. Cooke E.L. Li X. O'Neill L.A. Mol. Cell. Biol. 2001; 21: 4544-4552Crossref PubMed Scopus (71) Google Scholar). The Gal-luciferase reporter gene pFA-Jun and pFA-Elk-1 fusion vectors for analysis of JNK and P42/p44, respectively, were obtained from Stratagene (La Jolla, CA). Transient Transfections and Reporter Gene Assays—HEK293 cells (2 × 104) were seeded in 96-well plates 24 h prior to transfection. Transfections were performed with FuGENE 6 (Roche Diagnostics). Mal vectors (0.5–2 ng) and κB-luciferase were from Stratagene. NF-κB-dependent gene expression was determined using the 5× κB-luciferase reporter construct (Stratagene). Using the PathDetect transient transfection kit (Stratagene), co-transfection of pFR-luciferase in combination with Gal4-p65, pFA-Jun, or pFA-Elk-1 fusions, respectively, were used to analyze Mal/MalE190A activation of MAP kinase and p65 transactivation. The Rous sarcoma virus β-galactosidase construct was used to normalize for transfection efficiency, and pRSV empty vector was used to maintain constant DNA. Cells were left untreated or treated with 100 ng/ml Pam3Cys, 50 ng/ml K235 LPS, or 25 μg/ml pI:C for 4 h where indicated. Transfected cells were lysed using Passive lysis buffer (Promega, Madison, WI) and assayed for luciferase and β-galactosidase activity using luciferase assay reagent (Promega) or β-galactosidase assay reagent. Luminescence readings were corrected for β-Galactosidase activity and expressed as fold increase over non-stimulated control values or percentage stimulation. Statistical Analysis—Significance was evaluated using Student's t test for unpaired data. Immunoprecipitation and Western Blot Analysis—Immunoprecipitation and immunoblotting have been described previously (1Fitzgerald K.A. Palsson-McDermott E.M. Bowie A.G. Jefferies C.A. Mansell A.S. Brady G. Brint E. Dunne A. Gray P. Harte M.T. McMurray D. Smith D.E. Sims J.E. Bird T.A. O'Neill L.A. Nature. 2001; 413: 78-83Crossref PubMed Scopus (1005) Google Scholar). Western blot analysis was performed using anti-HA antibody (Rockland, Gilbertsville, PA) to detect Mal-Ha. Mal Associates with TRAF6 —Structural studies of TRAF6 in a complex with CD40 and TRANCE-R peptides suggested the structural determinant of the target protein contains a Pro-X-Glu-X-X-(aromatic/acidic residue) motif (18Ye H. Arron J.R. Lamothe B. Cirilli M. Kobayashi T. Shevde N.K. Segal D. Dzivenu O.K. Vologodskaia M. Yim M. Du K. Singh S. Pike J.W. Darnay B.G. Choi Y. Wu H. Nature. 2002; 418: 443-447Crossref PubMed Scopus (541) Google Scholar) for TRAF6 interaction. Analysis of the amino acid sequence of Mal indicated a putative TRAF6-binding domain at amino acid position 188–193 consisting of Pro-Pro-Glu-Leu-Arg-Phe similar to that described for IRAK and TRIF (Table I). Further analysis suggested that while Mal, TRIF, and TRAM all contain a putative TRAF6-binding motif, MyD88 does not, since the critical Glu residue (termed the P0 site) that has been found to confer specificity for TRAF6 interaction is changed to Ile in the corresponding MyD88 sequence (Table I). To test the hypothesis that Mal was therefore able to interact with TRAF6, co-precipitation experiments were carried out in HEK293T cells transiently transfected with FLAG-tagged TRAF6 and HA-tagged Mal. As shown in Fig. 1A (lane 1), we were able to detect complexes containing Mal- and TRAF6-tagged proteins by co-immunoprecipitation. To evaluate the functional regions involved in this association, the ability of Mal N-terminal region (amino acids 1–74) and the Mal-TIR region (amino acids 74–235) were also assayed for their ability to co-precipitate with TRAF6. As can be observed in lanes 2 and 3, while the N-terminal region of Mal is unable to associate with TRAF6, the Mal-TIR domain, which harbors the putative TRAF6-binding motif, does co-immunoprecipitate with TRAF6. We next mutated the putative TRAF6-binding motif in Mal by changing the glutamic acid at position 190 to alanine and tested the ability of the mutant to interact with TRAF6. Surprisingly, TRAF6 was found to still co-immunoprecipitate with MalE190A (Fig. 1A, lane 4). The mutated form of Mal did, however, affect the ability of TRAF6 to signal (Figs. 1B, 2, and 3). As can be seen in Fig. 1B, while TRAF6 overexpression induced NF-κB-dependent luciferase expression, MalE190A inhibited this effect in a dose-dependent manner. Furthermore, MalE190A had no effect the activation of NF-κB by overexpressed IKK2 at the maximal dose required to inhibit TRAF6-mediated signaling. This result indicates that the critical Glu at position 190 in Mal is required for TRAF6 to induce downstream signaling events.Fig. 2Mal interaction with TRAF6 mediates NF-κB activation and NF-κB transactivation. HEK293 cells (2 × 104) were transiently co-transfected with κB-luciferase and β-galactosidase reporter plasmids in conjunction with Mal or MalE190A. Readings are normalized for each sample as expressed κB-luciferase over constitutively expressed β-galactosidase and plotted as fold stimulation. Results are ±S.D. for triplicate determinations (n = 3). B, HEK293 cells (2 × 104) were co-transfected with the components of the with Mal and MalE190A Results are ±S.D. for triplicate determinations = (n = 3). HEK293 cells (2 × 104) were co-transfected with the components of the pFR-luciferase ng) and (2 ng) and ng) Gal4 fusion respectively, with Mal ng) and MalE190A ng) Results are ±S.D. for triplicate determinations = (n = TLR2- and TLR4-mediated NF-κB Cells (2 × 104) were co-transfected with κB-luciferase and β-galactosidase reporter in conjunction with a of MalE190A (0.5–2 respectively, for HEK293 TLR2- and cells and respectively, for stably transfected HEK293 Cells were with LPS Pam3Cys or pI:C where indicated for 6 of luciferase activity for triplicate determinations = = (n = The TRAF6-binding in Mal for Mal to type Mal was able to induce an increase in NF-κB-dependent luciferase expression in a dose-dependent manner. MalE190A, however, failed to induce luciferase expression over a corresponding dose (Fig. This result that the TRAF6-binding motif is required to mediate NF-κB activation by Mal. further signals by Mal were by mutation of the TRAF6 interaction motif. As can be seen in Fig. wild type Mal p65-mediated transactivation in a dose-dependent manner. The maximal activation of using this reporter is with the of activation previously reported in transactivation studies (20Jefferies C. Bowie A. Brady G. Cooke E.L. Li X. O'Neill L.A. Mol. Cell. Biol. 2001; 21: 4544-4552Crossref PubMed Scopus (71) Google Scholar). MalE190A failed to induce transactivation control at to wild type Mal. Mal was also unable to JNK or p42/p44 MAP kinase. As shown in Fig. overexpression of an dose of plasmid encoding Mal ng) was to drive and luciferase expression = and at with that which we have previously observed using reporter (1Fitzgerald K.A. Palsson-McDermott E.M. Bowie A.G. Jefferies C.A. Mansell A.S. Brady G. Brint E. Dunne A. Gray P. Harte M.T. McMurray D. Smith D.E. Sims J.E. Bird T.A. O'Neill L.A. Nature. 2001; 413: 78-83Crossref PubMed Scopus (1005) Google Scholar, E. M. M. O'Neill J. Biol. Chem. 2000; Full Text Full Text PDF PubMed Scopus Google Scholar). MalE190A was unable to induce luciferase expression that of control at These demonstrate that Mal mediates the activation of the MAP JNK and via its interaction with TRAF6. MalE190A TLR-mediated of we the role of interaction in TLR-mediated activation of NF-κB. HEK293 cells were transiently transfected with the luciferase reporter or them to the TLR Pam3Cys, pI:C, and As can be seen in Fig. 3, MalE190A was able to inhibit both TLR2- and TLR4-mediated activation of NF-κB-dependent luciferase expression in a dose-dependent manner. However, MalE190A was unable to inhibit activation of the κB-luciferase with studies no role for Mal in signaling M. Sato S. Hemmi H. Sanjo H. Uematsu S. Kaisho T. Hoshino K. Takeuchi O. Kobayashi M. Fujita T. Takeda K. Akira S. Nature. 2002; 420: 324-329Crossref PubMed Scopus (821) Google Scholar, K.A. Rowe D.C. Barnes B.J. Caffrey D.R. Visintin A. Latz E. Monks B. Pitha P.M. Golenbock D.T. J. Exp. Med. 2003; 198: 1043-1055Crossref PubMed Scopus (939) Google Scholar). results that the interaction between Mal and TRAF6 is necessary for the of NF-κB-dependent gene expression, upon and TLR4 stimulation. In this study we have found a feature in Mal that distinguishes it from MyD88. Mal has a TRAF6 interaction motif, which is required for Mal to The motif is for the of Mal, since a mutant form of Mal, MalE190A, which contains a mutation of a critical amino acid within the TRAF6-binding motif failed to p65-mediated transactivation of gene expression, luciferase expression, and activation of JNK and p42/p44 MAP kinase. MyD88 does not contain a putative TRAF6-binding motif and to TRAF6 via IRAK interaction with MyD88 is via domain interaction (5Janssens S. Beyaert R. Trends Biochem. Sci. 2002; 27: 474-482Abstract Full Text Full Text PDF PubMed Scopus (333) Google Scholar). the mutated MalE190A also as a TLR2- and TLR4-mediated activation of a NF-κB reporter results demonstrate that the interaction is required for signal transduction by TLR2 and the we a the role of Mal is to TLR2 and TLR4 with TRAF6, independent of MyD88 and IRAK that induce activation of the MAP kinase pathway and transactivation of the p65 subunit of NF-κB (Fig. 4). studies have shown that a corresponding in the TRAF6-binding motif of TRIF association (14Jiang Z. Mak T.W. Sen G. Li X. Proc. Natl. Acad. Sci. U. S. A. 2004; 101: 3533-3538Crossref PubMed Scopus (309) Google Scholar), results indicated that MalE190A was still able to associate with TRAF6. however, in the the of the interaction and signaling (14Jiang Z. Mak T.W. Sen G. Li X. Proc. Natl. Acad. Sci. U. S. A. 2004; 101: 3533-3538Crossref PubMed Scopus (309) Google Scholar, 15Sato S. Sugiyama M. Yamamoto M. Watanabe Y. Kawai T. Takeda K. Akira S. J. Immunol. 2003; 171: 4304-4310Crossref PubMed Scopus (590) Google Scholar). et al. (14Jiang Z. Mak T.W. Sen G. Li X. Proc. Natl. Acad. Sci. U. S. A. 2004; 101: 3533-3538Crossref PubMed Scopus (309) Google Scholar) found that TRIF could no TRAF6, and overexpression of this mutant failed to drive NF-κB activation as a in NF-κB activation (14Jiang Z. Mak T.W. Sen G. Li X. Proc. Natl. Acad. Sci. U. S. A. 2004; 101: 3533-3538Crossref PubMed Scopus (309) Google Scholar). Sato et al. (15Sato S. Sugiyama M. Yamamoto M. Watanabe Y. Kawai T. Takeda K. Akira S. J. Immunol. 2003; 171: 4304-4310Crossref PubMed Scopus (590) Google Scholar) a of association between TRIF and TRAF6 by the mutation of all three putative TRAF6-binding motifs in TRIF, with the of the Furthermore, reported that the mutant displayed a of NF-κB activation (15Sato S. Sugiyama M. Yamamoto M. Watanabe Y. Kawai T. Takeda K. Akira S. J. Immunol. 2003; 171: 4304-4310Crossref PubMed Scopus (590) Google Scholar), and the TRIF were required to inhibit NF-κB activation to a similar to that by et al. (14Jiang Z. Mak T.W. Sen G. Li X. Proc. Natl. Acad. Sci. U. S. A. 2004; 101: 3533-3538Crossref PubMed Scopus (309) Google Scholar). The to the to inhibit association and NF-κB activation suggested that the of an adapter as TRIF affect TRAF6 association and NF-κB of the association of MalE190A and TRAF6 a similar regions of Mal effect TRAF6 association that is not required for signal transduction. for the binding of Mal and TRAF6 in the absence of the P0 Glu is that the two and amino acids of MalE190A are still able to TRAF6 in via as by et al. (18Ye H. Arron J.R. Lamothe B. Cirilli M. Kobayashi T. Shevde N.K. Segal D. Dzivenu O.K. Vologodskaia M. Yim M. Du K. Singh S. Pike J.W. Darnay B.G. Choi Y. Wu H. Nature. 2002; 418: 443-447Crossref PubMed Scopus (541) Google Scholar) for TRANCE-R and TRAF6. However, the absence of the critical P0 Glu with TRAF6 TRAF6 unable to While study that Mal interaction with TRAF6 is there the that Mal interaction with IRAK Dunne and A. also to interaction with TRAF6 as is the with MyD88. The ability of Mal to interact with TRAF6 to TRAF6 to the signaling to that by the This NF-κB inducing a of However, the of cytokine expression in LPS-stimulated Mal-deficient macrophages (6Horng T. Barton G.M. Flavell R.A. Medzhitov R. Nature. 2002; 420: 329-333Crossref PubMed Scopus (689) Google Scholar, 7Yamamoto M. Sato S. Hemmi H. Sanjo H. Uematsu S. Kaisho T. Hoshino K. Takeuchi O. Kobayashi M. Fujita T. Takeda K. Akira S. Nature. 2002; 420: 324-329Crossref PubMed Scopus (821) Google Scholar) that the role of Mal is not to the pathway in TLR4 signaling but to a and necessary with The mutant Mal was unable to drive A signal was p65-mediated transactivation of gene This is the first of Mal this and it is that one for the of NF-κB-dependent gene expression in Mal-deficient NF-κB activation is that the signal for p65-mediated transactivation Mal. While the of regulating NF-κB activity is its in the by the transactivation of NF-κB to control gene expression is of critical to regulating the G. S. G. Biochem. 2002; PubMed Scopus Google Scholar). study that the interaction between Mal and TRAF6 is necessary for this transactivation. In we demonstrate Mal as a TRAF6 protein. The ability to the interaction between Mal and TRAF6 to control signaling and NF-κB-dependent gene expression, while not with the pathway of the TLRs, which are all MyD88. We Golenbock and Fitzgerald for the gift of the cells and for

References

18